Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 63-70

  Nakamura, K ^a   Abarzua, F ^a   Hongo, A ^a   Kodama, J ^a   Nasu, Y ^a   Kumon, H ^a   Hiramatsu, Y ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cervical cancer; Favorable prognosis marker, HAI 2

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; HEPSIN; MATRIPTASE; MEMBRANE PROTEIN; PROTEIN BAK; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UTERINE CERVIX CANCER;

EID: 58949095931     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn556     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Schwarz E, Freese UK, Gissmann L et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314: 111-114.
3. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996; 16: 1115-1125.
4. Comoglio PM. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS 1993; 65: 131-165.
5. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-Met receptor: a paradigm for mesenchymal/epithelial interactions. J Cell Biol 1994; 127: 1783-1787.
6. Baykal C, Ayhan A, Al A et al. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 2003; 88: 123-129.
7. Tsai HW, Chow NH, Lin CP et al. The significance of prohibitin and c-Met/ hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol 2006; 37: 198-204.
8. Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 6370-6376.
9. Kawaguchi T, Qin L, Shimomura T et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 27558-27564.
10. Kataoka H, Itoh H, Nuki Y et al. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator. Biochem Biophys Res Commun 2002; 290: 1096-1100.
11. Müller-Pillasch F, Wallrapp C, Bartels K et al. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrance domain overexpressed in pancreatic cancer. Biochim Biophys Acta 1998; 1395: 88-95.
12. Marlor CW, Delaria KA, Davis G et al. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J Biol Chem 1997; 272: 12202-12208.
13. Kataoka H, Shimomura T, Kawaguchi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40453-40462.
14. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-18242.
15. Kataoka H, Hamasuna R, Itoh H et al. Activation by hepatocyte growth factor/scatter in colorectal carcinoma. Cancer Res 2000; 60: 6148-6159.
16. Delaria KA, Muller DK, Marlor CW et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12209-12214.
17. Hamasuna R, Kataoka H, Meng JY et al. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: Implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer 2001; 93: 339-345.
18. Fukai K, Yokosuka O, Chiba T et al. Hepatocyte growth factor activator inhibitor 2/placental bikunin HAI-2/PB gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res 2003; 63: 8674-8679.
19. Betsunoh H, Mukai S, Akiyama Y et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007; 98: 491-498.
20. Suzuki M, Kobayashi H, Tanaka Y et al. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem 2003; 278: 14640-14646.
21. Suzuki M, Kobayashi H, Tanaka Y et al. Reproductive failure in mice lacking inter-alpha-trypsin inhibitor (ITI) - ITI target genes in mouse ovary identified by microarray analysis. J Endocrinol 2004; 183: 29-38.
22. Netzel-Arnett S, Hooper JD, Szabo R et al. Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003; 22: 223-236.
23. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-36725.
24. Takeuchi T, Harris JL, Huang W et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-26342.
25. Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 1995; 270: 66-72.
26. Krajewska M, Moss SF, Krajewski S et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56: 2422-2427.
27. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
28. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991; 88: 5523-5527.